A unique approach for discovering new autophagy therapeutics
The Lysoseeker™ Platform
,,,An unbiased, data-driven approach to discover new biology.
Lysoseeker™ is a set of capabilities which goes from screen to drug via new mechanisms and disease utility.
We start with an unbiased phenotypic screen and use proprietary technologies, including machine learning, to understand the mechanisms and targets of the autophagy-inducing molecules we identify.
We also screen these new molecules in a variety of translatable cellular models of disease.
With Lysoseeker™ we have discovered several highly promising lead molecules which are being optimised towards the clinic and restore autophagy in vivo via completely novel biology.
The process of autophagy features multiple steps and is highly dynamic.
We are building an understanding of these processes at a transcriptional and proteomic level and probing them with molecules to discover new intervention points, with the goal of boosting the whole process.
Our unbiased approach is leading to numerous opportunities for intervention.
The Lysoseeker™ Platform
A unique approach for discovering new autophagy therapeutics.
Neurodegeneration
What if we could tackle the cause of Alzheimer’s and Parkinson’s Disease?
Rare Monogenic Disease
What if we could offer real hope for serious rare genetic diseases?
Our Pipeline
Samsara is leveraging its knowledge of new autophagy biology.
Samsara Therapeutics adds eminent neurologist Professor Dame Pamela Shaw to its scientific advisory board to help accelerate ALS/MND treatment development
Samsara Therapeutics, the autophagy biotech company, has appointed eminent neurologist and world-leading researcher in Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Professor Dame Pamela Shaw to its scientific advisory board.
Samsara Therapeutics Parkinson’s drug receives funding boost from The Michael J. Fox Foundation
Samsara Therapeutics announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug.
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
Meet the Neuro Team – Modelling Neurodegeneration in a Dish
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy